Norio Ureshino

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Junichi Nakazawa · 13 shared papers, 2021–2025 · strength 1.68
   • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
   • Paper Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancrea… DOI 10.1038/s41598-024-55673-7↗
   • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
2. Kenji Mitsugi · 13 shared papers, 2021–2025 · strength 1.68
   • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
   • Paper Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancrea… DOI 10.1038/s41598-024-55673-7↗
   • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
3. Shiho Arima · 13 shared papers, 2021–2025 · strength 1.68
   • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
   • Paper Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancrea… DOI 10.1038/s41598-024-55673-7↗
   • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
4. Futa Koga · 13 shared papers, 2021–2025 · strength 1.68
   • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
   • Paper Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancrea… DOI 10.1038/s41598-024-55673-7↗
   • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
5. Taro Shibuki · 13 shared papers, 2021–2025 · strength 1.68
   • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
   • Paper Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancrea… DOI 10.1038/s41598-024-55673-7↗
   • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
6. Mototsugu Shimokawa · 13 shared papers, 2021–2025 · strength 1.68
   • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
   • Paper Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancrea… DOI 10.1038/s41598-024-55673-7↗
   • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
7. Masaru Fukahori · 13 shared papers, 2021–2025 · strength 1.68
   • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
   • Paper Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancrea… DOI 10.1038/s41598-024-55673-7↗
   • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
8. Taiga Otsuka · 13 shared papers, 2021–2025 · strength 1.68
   • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
   • Paper Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancrea… DOI 10.1038/s41598-024-55673-7↗
   • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
9. Tsuyoshi Shirakawa · 13 shared papers, 2021–2025 · strength 1.68
   • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
   • Paper Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancrea… DOI 10.1038/s41598-024-55673-7↗
   • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
10. Yasushi Ide · 13 shared papers, 2021–2025 · strength 1.68
    • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
    • Paper Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancrea… DOI 10.1038/s41598-024-55673-7↗
    • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
11. Azusa Komori · 13 shared papers, 2021–2025 · strength 1.68
    • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
    • Paper Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancrea… DOI 10.1038/s41598-024-55673-7↗
    • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
12. Hiroki Taguchi · 13 shared papers, 2021–2025 · strength 1.68
    • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
    • Paper Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancrea… DOI 10.1038/s41598-024-55673-7↗
    • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
13. Yoshinobu Okabe · 4 shared papers, 2021–2024 · strength 0.52
    • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
    • Paper Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the… DOI 10.1007/s10147-023-02354-6↗
    • Paper Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients wit… DOI 10.1038/s41598-023-46924-0↗
14. Yasunori Kawaguchi · 4 shared papers, 2021–2025 · strength 0.51
    • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
    • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
    • Paper Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-wo… DOI 10.1016/j.jgo.2021.06.011↗
15. Keisuke Miwa · 3 shared papers, 2023–2025 · strength 0.44
    • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
    • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
    • Paper Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients wit… DOI 10.1038/s41598-023-46924-0↗
16. Akio Ido · 3 shared papers, 2021–2023 · strength 0.33
    • Paper Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of t… DOI 10.1159/000527176↗
    • Paper Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Ob… DOI 10.1097/mpa.0000000000001859↗
    • Paper Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resectio… DOI 10.21873/anticanres.15145↗
17. Kazuo Nishikawa · 2 shared papers, 2024–2025 · strength 0.30
    • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
    • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
18. Shuji Arita · 2 shared papers, 2024–2025 · strength 0.30
    • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
    • Paper Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresecta… DOI 10.1038/s41598-024-65689-8↗
19. Eishi Baba · 2 shared papers, 2023–2024 · strength 0.30
    • Paper Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancrea… DOI 10.1038/s41598-024-55673-7↗
    • Paper C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated … DOI 10.1038/s41598-023-34962-7↗
20. Tomonori Araki · 1 shared paper, 2025 · strength 0.16
    • Paper Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Ca… DOI 10.1159/000542137↗
21. Tomoyuki Ushijima · 1 shared paper, 2023 · strength 0.14
    • Paper Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients wit… DOI 10.1038/s41598-023-46924-0↗
22. Shinichi Hashimoto · 1 shared paper, 2021 · strength 0.10
    • Paper Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After Resectio… DOI 10.21873/anticanres.15145↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.